A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?
Authors
Keywords
-
Journal
GENETICS IN MEDICINE
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-10-12
DOI
10.1038/s41436-020-00995-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data
- (2020) Nita A. Limdi et al. PHARMACOGENOMICS JOURNAL
- Reporting of race in genome and exome sequencing studies of cancer: a scoping review of the literature
- (2019) Adrienne Nugent et al. GENETICS IN MEDICINE
- Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases
- (2019) Ye Zhu et al. GENETICS IN MEDICINE
- Projected Costs of Informal Caregiving for Cardiovascular Disease: 2015 to 2035: A Policy Statement From the American Heart Association
- (2018) Sandra B. Dunbar et al. CIRCULATION
- Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers
- (2018) Jalpa A. Doshi et al.
- Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects
- (2018) Simona Volpi et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers
- (2018) Jalpa A. Doshi et al. Circulation-Cardiovascular Quality and Outcomes
- Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers
- (2017) Nicholas J Keeling et al. GENETICS IN MEDICINE
- Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial
- (2017) Dhruv S. Kazi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- PCSK9 Inhibitors
- (2017) Mark A. Hlatky et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cost-Effectiveness Analysis 2.0
- (2017) Peter J. Neumann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Warfarin Pharmacogenomics in Diverse Populations
- (2017) Justin B. Kaye et al. PHARMACOTHERAPY
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
- (2016) Gillian D. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Preemptive Pharmacogenomic Testing for Precision Medicine
- (2016) Yuan Ji et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Efficacy, Tolerability, and Dose-Dependent Effects of Opioid Analgesics for Low Back Pain
- (2016) Christina Abdel Shaheed et al. JAMA Internal Medicine
- Atrial fibrillation incidence and risk factors in relation to race-ethnicity and the population attributable fraction of atrial fibrillation risk factors: the Multi-Ethnic Study of Atherosclerosis
- (2015) Carlos J. Rodriguez et al. ANNALS OF EPIDEMIOLOGY
- Cost-Effectiveness and Population Impact of Statins for Primary Prevention in Adults Aged 75 Years or Older in the United States
- (2015) Michelle C. Odden et al. ANNALS OF INTERNAL MEDICINE
- Pharmacogenomics in the clinic
- (2015) Mary V. Relling et al. NATURE
- Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis
- (2015) Joyce HS You PHARMACOGENOMICS
- Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome
- (2014) Dhruv S. Kazi et al. ANNALS OF INTERNAL MEDICINE
- Anti-PCSK9 Monotherapy for Hypercholesterolemia
- (2014) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Preemptive Genotyping for Personalized Medicine: Design of the Right Drug, Right Dose, Right Time—Using Genomic Data to Individualize Treatment Protocol
- (2014) Suzette J. Bielinski et al. MAYO CLINIC PROCEEDINGS
- Cost-Effectiveness of Universal and Platelet Reactivity Assay-Driven Antiplatelet Therapy in Acute Coronary Syndrome
- (2013) Craig I. Coleman et al. AMERICAN JOURNAL OF CARDIOLOGY
- Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping
- (2012) J S Schildcrout et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis
- (2012) A. LALA et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Educational Needs of Primary Care Physicians Regarding Direct-to-Consumer Genetic Testing
- (2011) Karen P. Powell et al. Journal of Genetic Counseling
- The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects
- (2009) Deepak Voora et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation